COVID-19 y el impacto de la hipertensión arterial: un análisis del registro internacional HOPE COVID-19 (Italia-España-Alemania)

Loading...
Thumbnail Image
Identifiers

Publication date

Authors

El-Battrawy, Ibrahim
Abumayyaleh, Mohammad
Estrada, Vicente
Becerra Muñoz, Víctor Manuel

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Background: A systematic analysis of concomitant arterial hypertension in COVID-19 patients and the impact of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) have not been studied in a large multicentre cohort yet. We conducted a subanalysis from the international HOPE Registry (https://hopeprojectmd.com, NCT04334291) comparing COVID-19 in presence and absence of arterial hypertension. Materials and methods: Out of 5837 COVID-19 patients, 2850 (48.8%) patients had the diagnosis arterial hypertension. 1978/2813 (70.3%) patients were already treated with ACEI or ARBs. The clinical outcome of the present subanalysis included all-cause mortality over 40 days of follow-up. Results: Patients with arterial hypertension suffered significantly more from different complications including respiratory insufficiency (60.8% vs 39.5%), heart failure (9.9% vs 3.1%), acute kidney injury (25.3% vs 7.3%), pneumonia (90.6% vs 86%), sepsis (14.7% vs 7.5%), and bleeding events (3.6% vs 1.6%). The mortality rate was 29.6% in patients with concomitant arterial hypertension and 11.3% without arterial hypertension (P < .001). Invasive and non-invasive respiratory supports were significantly more required in presence of arterial hypertension as compared without it. In the multivariate cox regression analysis, while age≥65, benzodiazepine, antidepressant at admission, elevated LDH or creatinine, respiratory insufficiency and sepsis might be a positive independent predictors of mortality, antiviral drugs, interferon treatment, ACEI or ARBs at discharge or oral anticoagulation at discharge might be an independent negative predictor of the mortality. Conclusions: The mortality rate and in-hospital complications might be increased in COVID-19 patients with a concomitant history of arterial hypertension. The history of ACEI or ARBs treatments does not seem to impact the outcome of these patients.

Description

Keywords

Bibliographic reference

El-Battrawy, I., Núñez-Gil, I. J., Abumayyaleh, M., Estrada, V., Manuel Becerra-Muñoz, V., Uribarri, A., Fernández-Rozas, I., Feltes, G., Arroyo-Espliguero, R., Trabattoni, D., López-País, J., Pepe, M., Romero, R., Castro-Mejía, A. F., Cerrato, E., Capel Astrua, T., D'Ascenzo, F., Fabregat-Andres, O., Signes-Costa, J., Marín, F., … Akin, I. (2021). COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). European Journal of Clinical Investigation, 51(11), e13582. https://doi.org/10.1111/eci.13582

Type of document